Summary of ARIAD PHARMACEUTICALS INC

ITEM 2.02 Results of Operations and Financial Condition.

In a press release dated November 7, 2012, ARIAD Pharmaceuticals, Inc. (the "Company") announced financial results for the third quarter and nine months ended September 30, 2012. A copy of the press release is attached hereto as Exhibit 99.1. The information under the headings "Financial Highlights from the Third Quarter of 2012" and "Today's Conference Call Reminder" and the condensed consolidated financial information included in the press release are incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.

ITEM 7.01 Regulation FD Disclosure.

In the press release dated November 7, 2012, the Company also provided information on upcoming medical and investor meetings. The information set forth under the headings "Upcoming Medical Meeting" and "Upcoming Investor Meetings" in the press release is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

ITEM 8.01 Other Events.

In the press release dated November 7, 2012, the Company also provided an update on its ponatinib and AP26113 programs. The second paragraph of the press release and the information set forth under the headings "Ponatinib Clinical Development Progress," "Ready for U.S. Commercialization of Ponatinib" and "Advancing AP26113 Through Clinical Development" together with the forward-looking statement disclaimer at the end of the press release, are incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number  Description

99.1    Press release dated November 7, 2012.

The press release contains hypertext links to information on our website. The information on our website is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

THE PORTIONS OF THE PRESS RELEASE INCORPORATED BY REFERENCE INTO ITEM 8.01 OF THIS CURRENT REPORT ON FORM 8-K ARE BEING FILED PURSUANT TO ITEM 8.01. THE REMAINING PORTIONS OF THE PRESS RELEASE ARE BEING FURNISHED PURSUANT TO
ITEMS 2.02 AND 7.01 OF THIS CURRENT REPORT ON FORM 8-K AND SHALL NOT BE DEEMED "FILED" FOR PURPOSES OF SECTION 18 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED (THE "EXCHANGE ACT") OR OTHERWISE SUBJECT TO THE LIABILITIES OF THAT SECTION, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE IN ANY FILING UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE EXCHANGE ACT EXCEPT AS SHALL BE EXPRESSLY SET FORTH BY SPECIFIC REFERENCE IN SUCH FILING.